You may also like
PHVT Disruptive Technology Could Revolutionize Heart Failure Treatment
The early clinical promise of percutaneous heart valve technology-a group of minimally invasive devices designed to treat cardiac valve dysfunction without the need for cardiopulmonary bypass-could one day play a prominent role in curbing the costs associated with treating heart failure, which is the current number-one driver of hospitalization among Medicare patients.
Heparin-coated vs. Non-coated Cardiopulmonary Bypass Circuits: Comparing Immediate Results with Different Target Activated Clotting Time
Heparin-coated circuits and reduced level of systemic heparinization with 300 seconds of target ACT level in cardiac surgery under CPB are safe and result in a very satisfactory clinical course.
Double Bull’s Eye for Post-Operative Intravenous Iron in Patient Blood Management: Better Outcome and Cost-Effective
The results of this economic evaluation showed that iron-treated patients had a significantly lower allogeneic transfusion rate in comparison to control subjects